7 recruiting, 2 active not recruiting, 1 completed, 1 unknown. 11 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 7, Active not recruiting 2, Completed 1, Unknown 1 |
| Phase 1 | 6 | Recruiting 5, Active not recruiting 1 |
Follow Primary Mediastinal Large B-cell Lymphoma (PMBCL): new trials by email Literature Review of Primary Mediastinal Large B-cell Lymphoma (PMBCL) trials Research Report on Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma 7×19-THEMIS CAR-T cells - Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2026-09-01 | 2026-08-26 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells - Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | Malaghan Institute of Medical Research | 60 | 2024-07-12 | 2026-08-07 |
| Pembro Plus CAR T-cell Therapy in R/R in PMBCL Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion - Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma | Phase 2 | Recruiting | Jennifer Crombie, MD | 35 | 2023-11-15 | 2026-03-05 |
| Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients TC011 - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | TICAROS Co., Ltd. | 98 | 2023-08-03 | 2026-03-16 |
| A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) Pembrolizumab - Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Phase 2 | Completed | Merck Sharp & Dohme LLC | 66 | 2021-06-07 | 2026-10-27 |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients CRC01, Fludarabine, Cyclophosphamide - Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Curocell Inc. | 91 | 2021-03-02 | 2026-07-01 |
| Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy - Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 26 | 2021-02-18 | 2026-10-07 |
| Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma LP002 - Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Phase 2 | Unknown | Taizhou HoudeAoke Biomedical Co., Ltd. | 69 | 2020-12-30 | 2020-10-23 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells - Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL) | Phase 1 / Phase 2 | Recruiting | Medical College of Wisconsin | 100 | 2020-05-18 | 2026-02-23 |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma Epcoritamab - DLBCL, High-grade B-cell Lymphoma (HGBCL) | Phase 1 / Phase 2 | Active not recruiting | Genmab | 666 | 2018-06-26 | 2026-11-04 |
Lymphoma, Large B-Cell, Diffuse (7) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Burkitt Lymphoma (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Lymphoma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphoma (8) · Lymphoma, B-Cell (8) · Lymphoma, Non-Hodgkin (5) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Chronic Disease (3) · Hematologic Diseases (3)
Cyclophosphamide (3) · fludarabine (3) · pembrolizumab (2) · 13-valent pneumococcal vaccine (1) · Automobiles (1) · Leukapheresis (1) · Pneumococcal Vaccines (1) · Receptors, Chimeric Antigen (1)
Curocell Inc. (1) · Genmab (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jennifer Crombie, MD (1) · Malaghan Institute of Medical Research (1) · Medical College of Wisconsin (1) · Merck Sharp & Dohme LLC (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · TICAROS Co., Ltd. (1) · Taizhou HoudeAoke Biomedical Co., Ltd. (1) · Vironexis Biotherapeutics Inc. (1)
United States (6) · South Korea (3) · Canada (2) · China (2) · France (2) · Italy (2) · Poland (2) · Australia (1) · Brazil (1) · Czechia (1) · Denmark (1) · Finland (1) · Germany (1) · Netherlands (1) · New Zealand (1)
Frederick Locke, MD (1) · Jennifer Crombie, MD (1) · Nirav Shah, MD (1) · Philip George, MBChB (1) · Robert Weinkove, PhD (1) · Wenbin Qian,Professor (1) · Yuankai Shi, MD (1)
PMID 34508654, PMID 34628052, PMID 35597752, PMID 36548927, PMID 38151388, PMID 38889737, PMID 39322711, PMID 40163793, PMID 40472301, PMID 42212152, PMID 42284198, PMID 42411504, PMID 42431612, PMID 42541678
2017 (1), 2023 (1)